Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/04/2003US20030225050 Process for production of crystals of 11ss-benzaldoxim-estra-4,9-diene derivatives, crystals obtained thereby and pharmaceutical preparations containing them
12/04/2003US20030225033 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
12/04/2003US20030225029 Dosing regimen for gemcitabine HCV therapy
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224971 Manufacture of polyglutamate-therapeutic agent conjugates
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224414 Comprises nucleotide sequences coding enzymatic polypeptide for diagnosis, prognosis and treatment of cell proliferative disorders
12/04/2003US20030224413 Comprises polynucleotides coding restriction fragment length polymorphism for use in identifying, characterizing and treatment of blood, respiratory, tumor and nervous system disorders
12/04/2003US20030224402 Progression suppressed gene 13 (PSGen 13) and uses thereof
12/04/2003US20030224377 Novel LNA compositions and uses thereof
12/04/2003US20030224360 Interventions to mimic the effects of calorie restriction
12/04/2003US20030224076 Anti-inflammatory and chemopreventive composition
12/04/2003US20030224040 Genomic screen for epigenetically silenced genes associated with cancer
12/04/2003US20030224037 An antitumor agent oxaliplatin in transferrins liposome ligand and polyoxyethylene glycol, improving the storage stability, detoxifying and inhibiting the side effect caused by therapeutic drug
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030223999 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
12/04/2003US20030223994 Protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223990 A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. 193P1E1 provides
12/04/2003US20030223971 Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
12/04/2003US20030223969 Method of modulating inflammatory response
12/04/2003US20030223958 Use of interleukin-19 to treat ovarian cancer
12/04/2003US20030223956 Macromers having a backbone comprising a polymeric backbone comprising units with a 1,2- diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and other modifiers. When crosslinked, the macromers
12/04/2003US20030223938 Relates to nanoparticles comprised of a carrier, particularly polymerized lipids, and ligands displayed on the carrier, wherein the ligands form a polyvalent binding unit that is effective to produce a specific interaction between the
12/04/2003CA2513388A1 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
12/04/2003CA2487811A1 Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487452A1 A method for generating antigen-presenting cells
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487268A1 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487117A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2487017A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486918A1 Novel chimeric cd154
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486716A1 Compositions and their uses for alleviating pain
12/04/2003CA2486704A1 Anti-cancer formulation
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2485816A1 Vaccines
12/04/2003CA2485733A1 Vaccines
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484656A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2484000A1 Neutralizing human anti-igfr antibody
12/04/2003CA2483627A1 Mitotic kinesin inhibitors
12/04/2003CA2478833A1 Anti-.alpha.v.beta.6 antibodies
12/03/2003EP1367057A1 Epothilones C, E and F
12/03/2003EP1367051A2 Inhibitors of tumor necrosis factor alpha
12/03/2003EP1367046A1 Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs
12/03/2003EP1366773A1 Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
12/03/2003EP1366768A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
12/03/2003EP1366673A2 Carob product based antiinflammatory or chemopreventative agent
12/03/2003EP1366366A2 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
12/03/2003EP1366180A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
12/03/2003EP1366173A2 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
12/03/2003EP1366167A2 Biological organism for preparing pharmaceutical compositions for treating mammals
12/03/2003EP1366165A2 G-protein coupled receptors
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366158A2 Trp8, trp9 and trp10, markers for cancer
12/03/2003EP1366157A2 Compositions and methods for the therapy and diagnosis of lung cancer
12/03/2003EP1366153A2 Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
12/03/2003EP1366152A2 G-protein coupled receptors
12/03/2003EP1366150A2 Use of protein histidine phosphatase
12/03/2003EP1366144A2 A device for preparing cells
12/03/2003EP1366082A1 Highly sulfated derivatives of k5 polysaccharide and their preparation
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366075A2 New interferon beta-like molecules
12/03/2003EP1366064A1 Tumour targeting prodrugs activated by metallo matrixproteinases
12/03/2003EP1366063A2 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancr
12/03/2003EP1366062A2 Efficient recovery of correctly refolded proteins
12/03/2003EP1366055A2 Antiviral agents for treatment of flaviviridae infections
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366040A2 Amorphous form of cell cycle inhibitor
12/03/2003EP1366038A1 Cdk-1 inhibitor oxindoles and the application thereof in therapeutics
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366029A1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366022A1 Rgd-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects
12/03/2003EP1366021A2 Substituted diarylureas as stimulators for fas-mediated apoptosis
12/03/2003EP1366012A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
12/03/2003EP1365808A2 Compositions for antitumour treatment containing ecteinascidin 743
12/03/2003EP1365805A2 Novel targeted compositions for diagnostic and therapeutic use
12/03/2003EP1365800A2 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/03/2003EP1365797A2 Methods and agents modulating upa/upar activity
12/03/2003EP1365796A2 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
12/03/2003EP1365781A1 Acrochordon alleviation
12/03/2003EP1365777A2 Proteoglycan compositions for treatment of inflammatory conditions
12/03/2003EP1365774A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes
12/03/2003EP1365768A2 Use of erss-selective ligands for regulating fertility and compounds useful therefore
12/03/2003EP1365763A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
12/03/2003EP1365762A1 Method for increasing leptin levels using nicotinic acid compounds
12/03/2003EP1365760A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/03/2003EP1365759A2 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
1 ... 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 ... 2211